Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when UNCY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsUnicycive reports Q1 2026 financial results and business update
Filed May 12, 2026 · Period ending May 12, 2026 · ~1 min read
Key Changes
-
medium
Company announced financial results for the quarter ended March 31, 2026, along with a business update via press release dated May 12, 2026.
Item 7.01 view on EDGAR → -
low
Full financial details and business update are contained in the attached press release (Exhibit 99.1), not disclosed in the 8-K body itself.
Exhibit 99.1 view on EDGAR →
Summary
Unicycive Therapeutics filed an 8-K to announce its first quarter 2026 financial results and provide a business update. The disclosure was made through a press release dated May 12, 2026, attached as an exhibit to the filing. The 8-K itself does not contain the actual financial figures or details of the business update.
Retail investors should review the full press release (Exhibit 99.1) to understand the company's Q1 performance, including revenue, expenses, cash position, and any operational milestones achieved during the quarter. As a clinical-stage biopharmaceutical company, key metrics to watch include cash runway, clinical trial progress, and any updates on the company's lead programs. Investors should monitor whether the company provides guidance on upcoming catalysts or funding needs in subsequent disclosures.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Unicycive filed an 8-K attaching a press release dated May 12, 2026; no material event details disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1 Press Release of Unicycive Therapeutics, Inc. dated May 12, 2026.
The 8-K discloses that a press release dated May 12, 2026 has been attached as Exhibit 99.1. The filing body does not describe the content or subject matter of the press release, so the nature of the disclosed event cannot be determined from this 8-K alone.
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 12, 2026, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026 and provided a business update.
The company disclosed its financial results for the quarter ended March 31, 2026, along with a business update. The actual financial figures and business details are contained in the press release (Exhibit 99.1), which is not included in this 8-K body.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify